A detailed history of Aqr Capital Management LLC transactions in Ideaya Biosciences, Inc. stock. As of the latest transaction made, Aqr Capital Management LLC holds 15,752 shares of IDYA stock, worth $418,058. This represents 0.0% of its overall portfolio holdings.

Number of Shares
15,752
Previous 15,632 0.77%
Holding current value
$418,058
Previous $548,000 8.94%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$30.37 - $43.05 $3,644 - $5,166
120 Added 0.77%
15,752 $499,000
Q2 2024

Aug 14, 2024

SELL
$34.37 - $43.46 $43,443 - $54,933
-1,264 Reduced 7.48%
15,632 $548,000
Q1 2024

May 15, 2024

BUY
$34.2 - $47.13 $34,781 - $47,931
1,017 Added 6.4%
16,896 $741,000
Q4 2023

Feb 14, 2024

SELL
$24.59 - $35.83 $29,630 - $43,175
-1,205 Reduced 7.05%
15,879 $564,000
Q3 2023

Nov 14, 2023

BUY
$21.07 - $29.77 $96,395 - $136,197
4,575 Added 36.57%
17,084 $460,000
Q2 2023

Aug 14, 2023

BUY
$13.33 - $25.53 $166,744 - $319,354
12,509 New
12,509 $293,000
Q1 2022

May 16, 2022

SELL
$11.18 - $24.02 $137,916 - $296,310
-12,336 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$20.95 - $26.88 $258,439 - $331,591
12,336 New
12,336 $292,000
Q3 2021

Nov 15, 2021

SELL
$17.26 - $27.08 $428,962 - $673,019
-24,853 Closed
0 $0
Q2 2021

Aug 16, 2021

SELL
$17.76 - $24.83 $110,342 - $154,268
-6,213 Reduced 20.0%
24,853 $522,000
Q1 2021

May 17, 2021

SELL
$13.48 - $23.77 $106,397 - $187,616
-7,893 Reduced 20.26%
31,066 $730,000
Q4 2020

Feb 16, 2021

BUY
$12.17 - $17.52 $474,131 - $682,561
38,959 New
38,959 $545,000

Others Institutions Holding IDYA

About IDEAYA Biosciences, Inc.


  • Ticker IDYA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,067,700
  • Market Cap $1.28B
  • Description
  • IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinica...
More about IDYA
Track This Portfolio

Track Aqr Capital Management LLC Portfolio

Follow Aqr Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Aqr Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Aqr Capital Management LLC with notifications on news.